Chardan Capital Lowers Femasys (NASDAQ:FEMY) Price Target to $8.00

Femasys (NASDAQ:FEMY) had its price target lowered by Chardan Capital from $10.00 to $8.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Femasys in a research note on Tuesday.

Femasys Price Performance

Shares of FEMY remained flat at $1.03 during midday trading on Wednesday. The stock had a trading volume of 308,506 shares, compared to its average volume of 333,667. Femasys has a twelve month low of $0.73 and a twelve month high of $2.40. The company has a debt-to-equity ratio of 0.43, a current ratio of 6.47 and a quick ratio of 5.93. The stock has a market cap of $22.90 million, a P/E ratio of -1.27 and a beta of -2.83. The firm has a fifty day simple moving average of $1.16 and a 200-day simple moving average of $1.15.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The firm had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative return on equity of 120.13% and a negative net margin of 1,435.77%. As a group, equities research analysts expect that Femasys will post -0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Femasys

A hedge fund recently bought a new stake in Femasys stock. Aljian Capital Management LLC purchased a new position in shares of Femasys Inc. (NASDAQ:FEMY) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 24,768 shares of the company’s stock, valued at approximately $27,000. Aljian Capital Management LLC owned 0.11% of Femasys as of its most recent SEC filing. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.